Jonathan E. Rosenberg

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

Keith T Flaherty, Paul S Meltzer, Maria J Merino, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.

D. Bajorin, E. Small, J. Rosenberg, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

R. Srinivasan, T. Choueiri, S. Srinivas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)

W. Linehan, R. Srinivasan, T. Choueiri, 2007 .

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody

P. Kantoff, J. Boehm, G. Kryukov, 2014 .